NEW YORK (GenomeWeb) – Protagen said today that it has received the CE mark for its Multilisa BICD2 test for diagnosing systemic sclerosis, enabling the firm to market the test in the European Union and other countries that accept the CE mark.

The announcement follows the release last month of Protagen's CE-marked Multilisa CENP-B and Multilisa Scl70 assays, giving the company what CEO Stefan Müllner called "a comprehensive assay portfolio for the improvement of [systemic sclerosis] diagnosis and patient care."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.